I'm LongbridgeAI, I can summarize articles.J.P. Morgan analyst Lisa Gill maintained a Buy rating on Labcorp (LH) on August 10, citing the company's regulatory resilience and strategic upside in adapting to healthcare policy changes. Mizuho Securities also issued a Buy rating with a $355 price target on the same date.
J.P. Morgan analyst Lisa Gill has maintained their bullish stance on LH stock, giving a Buy rating on August 10.
Lisa Gill’s rating is based on Labcorp’s solid positioning within a complex but ultimately supportive regulatory landscape and the company’s ability to adapt to evolving healthcare policy. She appears to view the current environment as offering manageable risk relative to Labcorp’s scale, capabilities, and track record in navigating rule changes, which underpins confidence in future earnings stability.
At the same time, Gill likely sees incremental upside as Labcorp leverages regulatory clarity to expand services, optimize reimbursement, and deepen relationships with payors and providers. In her view, this combination of regulatory resilience and strategic opportunity supports a favorable risk‑reward profile for the stock, warranting an Overweight/Buy recommendation.
In another report released on August 10, Mizuho Securities also maintained a Buy rating on the stock with a $355.00 price target.